pp-232 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Geographic Atrophy (retinal disease) / Clinical stage: Phase 2 / Modality: Biologic - novel complement inhibitor / Mechanism & Target: Next-generation complement pathway inhibitor / Route & form: SC or IV / Differentiation: Combination therapy approach; comprehensive complement blockade
Manufacturer #39439
| International biotechnology company focused on rare and severe autoimmune diseases. Develops FcRn-modulating and complement-targeting biologics for neuromuscular and immune-mediated conditions. Advances multiple Phase 3 programs through global clinical development. |
None